Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

2.100 -0.080 (-3.67%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 20.46% to $0.8 during Thursday's pre-market session. The company's market cap stands at $68.5 million... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) stock increased by 21.06% to $1.31 during Thursday's regular session. The current volume of 70.4 million shares is 943.37% of Progenity... 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Xeris Pharmaceuticals (NASDAQ:XERS 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Brickell Biotech (NASDAQ:BBI) stoc... 
Via Benzinga
News headline image
Want to Buy CNS Pharmaceuticals (NASDAQ: CNSP) Stock? Read This First. ↗
CNS Pharmaceuticals (NASDAQ: CNSP) is a pre-clinical biotech company focusing on treatments for brain tumors. The firm holds the exclusive worldwide license for its main... 
Via Benzinga
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Via FinancialNewsMedia
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Via FinancialNewsMedia
News headline image
CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin ↗
CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma... 
Via Benzinga
News headline image
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin ↗
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. 
Via Talk Markets
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.